Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Deloitte
UBS
AstraZeneca
Covington
Argus Health
Chubb
Julphar
Boehringer Ingelheim

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,536,729

« Back to Dashboard

Summary for Patent: 5,536,729
Title: Rapamycin formulations for oral administration
Abstract:The present invention provides novel oral rapamycin formulations which have, per 100 ml of the formulation, from about 0.01 grams to about 5.0 grams of rapamycin, from about 0.05% to about 10% by volume of surfactant, and from about 75% to about 99.95% by volume of a solution of phospholipid or lecithin in which the phospholipid or lecithin therein is 40% to 75% by weight.
Inventor(s): Waranis; Robert P. (Chazy, NY), Leonard; Thomas W. (Willmington, NC)
Assignee: American Home Products Corporation (Madison, NJ)
Application Number:08/301,179
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form;

Drugs Protected by US Patent 5,536,729

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 5,536,729

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 0648494 ➤ Sign Up C00648494/01 Switzerland ➤ Sign Up
European Patent Office 0648494 ➤ Sign Up SPC/GB01/037 United Kingdom ➤ Sign Up
European Patent Office 0648494 ➤ Sign Up SPC020/2001 Ireland ➤ Sign Up
European Patent Office 0648494 ➤ Sign Up 01C0037 France ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Cantor Fitzgerald
Harvard Business School
Moodys
McKinsey
Argus Health
Dow
Daiichi Sankyo
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.